Chronic Obstructive Pulmonary Disease (COPD) – GSK 222714-222725

The aim of this study is to assess the efficacy and safety of Depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Inclusion Criteria:

• Participants must be greater than or equal to (>=) 40 to less than or equal to (<=) 80 years of age, at the time of signing the Informed consent
• Elevated Blood Eosinophil Count (BEC)
• Moderate to severe COPD with frequent exacerbations
• COPD assessment test (CAT) score >=10 at Visit 1
• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years.
• Participants should be on optimized inhaler therapy
• Body mass index (BMI) >=16 kilogram per square meter (kg/m^2)
• Male and eligible female participants
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.